New inhaler drug shows promise for COPD inflammation

NCT ID NCT05270525

Recruiting now Disease control Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a nebulized drug called ensifentrine can reduce inflammation in the lungs of people with COPD. About 56 adults aged 40-80 who smoke or have smoked will receive both the drug and a placebo at different times over 24 weeks. The main goal is to see changes in sputum cell counts, which indicate inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35205, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Email: •••••@•••••
University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.